| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-21 | 142.80 | 19.88 | 22.77p | 54.0 | n/a | n/a | n/a | 0.0% |
| 31-Dec-22 | 139.99 | (45.98) | (41.29)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-23 | 89.54 | (188.53) | (163.11)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-24 | 128.80 | (47.27) | (41.75)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-25 | 168.74 | (31.94) | (26.92)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Director dealings: Oxford Biomedica chair ups st... | 24-Sep-2026 |
| Oxford Biomedica delivers solid H1 growth, recor... | 22-Sep-2026 |
| Deutsche Bank downgrades Oxford Biomedica after ... | 18-Aug-2026 |
| Traded | Action | Notifier | Price | Amount | Value |
|---|---|---|---|---|---|
| 28-Sep-26 | Buy | Peter Soelkner | 511.24p | 1,672 | £8,547.91 |
| 25-Sep-26 | Buy | Peter Soelkner | 516.92p | 1,667 | £8,615.29 |
| 23-Sep-26 | Buy | Roch Doliveux | 505.00p | 20,250 | £102,262.50 |
| Currency | UK Pounds |
| Price | 514.00p |
| Change Today | 3.00p |
| 52 Week High | 913.00p |
| 52 Week Low | 424.00p |
| Volume | 257,643 |
| Shares Issued | 121.06m |
| Market Cap | £622.22m |
| Strong Buy | 3 |
| Buy | 1 |
| Neutral | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 8 |
